london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

Ranibizumab in the AMD wet formtreatment – 2 year results obtained from the AMADEuS registry

Poster Details

First Author: V.Matuskova CZECH REPUBLIC

Co Author(s):    P. Kolář   D. Vysloužilová   E. Vlková   L. Dušek   J. Jarkovský      0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

The aim of this study is the retrospective follow up of patients with wet form of Age-Related Macular Degeneration (AMD) treated with ranibizumab during 24 months period. The data were recorded into the AMADEuS (Age-relatedMAcularDEgeneration in patientS in the Czech Republic) Registry.

Setting:

The aim of this study is the retrospective follow up of patients with wet form of Age-Related Macular Degeneration (AMD) treated with ranibizumab during 24 months period. The data were recorded into the AMADEuS (Age-relatedMAcularDEgeneration in patientS in the Czech Republic) Registry (http://amadeus.registry.cz)

Methods:

The study group consisted of patiens registered since October 1st 2008 until September 9th 2013 in AMADEuS Registry, followed up for 24 months period. There were 224 eyes. All patiens underwent complete examination in the Macular Department of the Department of Ophthalmology in the Faculty Hospital Brno-Bohunice, Czech Republic, E.U. Consequently the ranibizumab (Lucentis, Novartis) was applied intravitreally in three initial doses monthly. Thereafter, ranibizumab was applied “on demand”. In 45.1 % of eyes the classical, in 29.5 % of eyes occult, and in 25.4 % of eyes the minimal classical chorioidal neovascular membrane was present. The initial visual acuity was in 2.7 % of eyes in the range 15 – 30 letters of ETDRS optotypes (20/500 – 20/200), in 58.0 % ofeyes in therange 31 – 60 letters (20/200 – 20/63), and the visual acuity bettert han 61 letters of ETDRS optotypes (better than 20/63) was in 39.3 % of eyes.

Results:

The ranibizumab monotherapy was present in 85% of patient, the swith to another therapy was necessary in 15 % of patients. The average number of ranibizumab doses during the follow-up period was 5.4 in ranibizumab monotherapy. After the 24 month follow-up period, the gain of 15 or more letters of EDTRS was recorded in 7.9 % of patients, the gain of 1 – 14 letters of EDTRS optotypes was recorded in 31.1 % of patients, the decrease of 14 or less letters of EDTRS optotypes was found in 38.4 % of patients, and the decrease of 15 or more letters was found in our group in 22.6 % of patients.

Conclusions:

According to our dates the ranibizumab is effective and availabletheraphy for patients with wet form of AMD. The national registr AMADEuS is of great importance in comparing of therapeutic results of our Macular centre to to other centres in our republic.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy